BPC-157: benefits, side effects and what the research shows

BPC-157 is a pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV ^[2]. It was described in 1993 by a research group at the University of Zagreb led by Predrag Sikirić, which reported isolating a larger protein, which it called BPC, from gastric juice and characterising a 15-amino-acid fragment thought to carry its activity ^[1]. The name stands for “Body Protection Compound”. The peptide used in research and sold online is made synthetically rather than extracted.

For most of its history BPC-157 was studied by a small number of groups, and the Zagreb group produced the large majority of papers. A 2019 review from Loughborough University noted that “only a handful of research groups” had studied it in depth and that most work was in small rodent models ^[5]. In the early 2000s it was described as being in clinical trials for inflammatory bowel disease under the codes PL 14736 and PLD-116 ^[2], but no results of those trials appear in the peer-reviewed literature we could find.

BPC-157 is one of the most widely discussed peptides sold as a “research chemical”, often alongside TB-500. For background on what that label means and why it matters, see what research peptides are.

In short, what BPC-157 is used for in research is tissue repair: tendon, ligament, muscle, bone and gut injuries in rats. What it is used for outside research, in clinics and by individuals, runs well ahead of that evidence, which is why this page separates animal findings from the small amount of human data.

No single receptor for BPC-157 has been identified, and proposed mechanisms come from cell and animal experiments. The most consistent theme is blood-vessel formation (angiogenesis). In a 2017 study, BPC-157 increased vessel density in a chick embryo assay and in cultured human endothelial cells, sped recovery of blood flow in rats with an ischaemic hind limb, and increased expression and activation of VEGFR2, a receptor for the growth factor VEGF, along with the downstream Akt–eNOS signalling pathway ^[4].

Tendon cell work points to effects on cell movement rather than cell division. In rat tendon fibroblasts, BPC-157 did not directly increase proliferation but did increase cell survival under oxidative stress and increased migration in a dose-dependent way, which the authors linked to activation of the FAK–paxillin pathway ^[3]. Reviews also describe interactions with the nitric oxide system and reduced inflammatory signalling, but these are drawn from animal models and have not been confirmed in people ^{[6] [7]}.

A 2015 study from a separate Chinese group reached a similar picture in skin: BPC-157 applied to alkali burns in rats sped wound closure and increased VEGF in the wounded tissue, and in cultured human endothelial cells it increased proliferation, migration and tube formation ^[25]. None of these mechanism studies measured anything in people.

The best-known experiment is a 2003 rat study in which the Achilles tendon was cut and animals received daily intraperitoneal BPC-157 or saline for up to 14 days. Treated rats showed higher load to failure, better functional scores and more organised collagen and fibroblast formation than controls ^[2]. Similar positive results from the same group followed for muscle and tendon-to-bone injuries, which are summarised in reviews ^{[5] [6]}.

Muscle work follows the same pattern. In a 2006 study, rats had the quadriceps muscle cut completely and were given daily intraperitoneal BPC-157 at 10 µg/kg, 10 ng/kg or 10 pg/kg. The authors reported better load to failure, walking recovery and muscle fibre regeneration throughout a 72-day follow-up ^[16]. A 2021 study from the same group found similar results when the quadriceps tendon was detached from the muscle, with BPC-157 given either by injection or in drinking water ^[17]. Searches for “BPC-157 muscle growth” usually mean building muscle in healthy people; these studies looked at repair after injury, and we found no study of BPC-157 and muscle growth in uninjured animals or humans.

A 2025 systematic review in HSS Journal screened 544 records and included 36 studies, of which 35 were preclinical and one was a clinical study. It concluded that BPC-157 improved functional, structural and biomechanical outcomes in animal models of muscle, tendon, ligament and bone injury, but graded the evidence as level IV and V and found no clinical safety data ^[6]. A 2025 narrative review from the University of Utah reached the same overall view: broad preclinical support, extremely limited human data, and a recommendation that BPC-157 be treated as investigational ^[7]. A 2026 scoping review in the American Journal of Sports Medicine, which covered BPC-157 alongside TB-500, CJC-1295, ipamorelin, MK-677 and GHK-Cu, found that 67% of publications used animal models and concluded that the claimed musculoskeletal benefits of these peptides are not supported by current human trials ^[19].

An independent 2026 study from Turkey compared BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day) and the two combined after surgical Achilles repair in 32 rats. BPC-157 produced numerically better tissue scores that did not reach statistical significance for the total scores, while TB-500 showed a significant biomechanical advantage at four weeks; the combination was no better than either alone ^[12]. This is one of the few studies from outside the original research group, and its results for BPC-157 were weaker than earlier reports.

BPC-157 was first investigated as a gut-protective agent. The 1993 overview from its discoverers reported protective effects across many organ systems in several species at very low doses, mostly in the microgram and nanogram per kilogram range ^[1]. Later work from the same group covered stomach and intestinal lesions, fistulas and anastomoses in rats. These are animal findings, often from a single laboratory, and should not be read as evidence of effect in people.

A 2012 review by the originating group described BPC-157 as stable in human gastric juice and said that, as PL 14736, it had been tested in phase II trials for inflammatory bowel disease ^[18]. The review summarised rat work on colitis, intestinal anastomosis healing, short bowel syndrome and fistulas. We could not find published results from the phase II bowel trials, so there are no peer-reviewed human data on BPC-157 for gut health, ulcerative colitis or Crohn’s disease.

People searching for BPC-157 for gut health often compare it with KPV, a small anti-inflammatory peptide studied in mouse colitis. Neither has published human trial results for bowel disease. Our KPV vs BPC-157 comparison sets the two side by side.

We found no study that tested BPC-157 for weight loss in animals or people. The closest work is a 2018 review, co-authored by the peptide’s discoverer, that proposed BPC-157 as a possible treatment for cancer cachexia, the involuntary muscle and fat loss seen in advanced cancer; that is the opposite problem, and the review called for clinical trials rather than reporting any ^[26]. Peptides that do have trial evidence for weight loss, such as semaglutide, work through different hormone pathways and are covered on their own pages.

No published study has compared the effects or side effects of BPC-157 in women and men. Most rat studies used a single sex, and the human literature is too small to separate results by sex. The only human study limited to one sex was the interstitial cystitis pilot, in which all 12 participants were women ^[9]. Claims about benefits specific to women or men therefore have no direct evidence behind them.

There are no published randomised controlled trials of BPC-157. Three small reports, all led by the same first author at private US clinics and published in Alternative Therapies in Health and Medicine, make up the human literature ^[7].

The first was a retrospective chart review of 16 people who had received knee injections. Of 12 who received BPC-157 alone, the authors reported that 11 described significant improvement in pain; four others received BPC-157 with thymosin beta-4. Pain was assessed by telephone survey, with no validated scoring tools and no control group ^[8]. A later systematic review summarised the same study as 7 of 12 patients reporting relief lasting more than six months, which shows how loosely the outcomes were defined ^[6].

The second was a pilot study in 12 women with interstitial cystitis who had not responded to pentosan polysulfate. Each received injections totalling 10 mg of BPC-157 into the bladder wall during a single cystoscopy. The authors reported complete symptom resolution in 10 of 12 and no adverse events, but there was no placebo group ^[9]. The third was a safety pilot in just two adults, who received 10 mg and then 20 mg of BPC-157 by intravenous infusion on consecutive days, with no changes in the blood markers tested and no reported side effects ^[10].

These reports are too small and too uncontrolled to establish whether BPC-157 works or is safe in people.

On ClinicalTrials.gov, a phase 1 study of an oral tablet containing BPC-157 (called PCO-02) in healthy volunteers was registered in 2015 by a Croatian company, with a planned 42 participants. Its status has not been updated since December 2015 and no results are posted ^[21]. A small randomised pilot of BPC-157 after arthroscopic rotator cuff repair, sponsored by the University of Arkansas, was registered in 2026 and was listed as not yet recruiting when we checked ^[22]. Until trials like these report, any BPC-157 human clinical trial claim should be checked against the registry.

In rats, most studies report differences between treated and untreated animals within days to weeks of an injury. The Achilles tendon study measured outcomes up to 14 days ^[2], the myotendinous junction study at 7, 14, 28 and 42 days ^[17], and the quadriceps study followed rats for 72 days ^[16]. These timepoints describe healing in rodents under controlled injuries and do not translate into a human timeline.

In people, there is no controlled evidence on how long BPC-157 takes to work, or whether it works at all. The knee pain review relied on recalled pain months after injection ^[8], and the interstitial cystitis pilot had no comparison group ^[9]. Online “BPC-157 before and after” photos and reviews cannot separate any effect of the peptide from natural healing, rest, physiotherapy or placebo, and the contents of the product used are rarely verified.

Most animal studies gave BPC-157 by injection into the abdominal cavity (intraperitoneal), which is not how people use it. Some studies from the Zagreb group also gave it by mouth in drinking water; in the 2021 myotendinous junction study, rats drank water containing 0.16 µg/mL and the authors reported effects similar to injection ^[17]. The same group describes BPC-157 as stable in human gastric juice ^[18]. We found no published human study measuring how much BPC-157 reaches the blood after swallowing it, so the oral bioavailability of BPC-157 capsules, tablets or pills in people is unknown.

For BPC-157 oral vs injection, the only direct pharmacokinetic data are from rats and dogs given intramuscular or intravenous doses, discussed under half-life below ^[11]. The one registered oral human study, of the PCO-02 tablet, has posted no results ^[21]. Products sold as BPC-157 capsules or supplements have not been tested in published trials, and their contents are not verified by any regulator.

We found no published study of BPC-157 nasal spray. A 1997 rat study of irritant-induced rhinitis is sometimes cited, but in that study BPC-157 was injected into the abdomen before the irritant was put in the nose ^[23]. Topical use has one animal study: BPC-157 applied to alkali burns on rat skin sped wound closure ^[25]. No human study of a BPC-157 cream has been published. We also found no peer-reviewed study comparing the arginate salt form of BPC-157 with the more common acetate form.

Questions such as where to inject BPC-157 or how to inject it are about practice, not research, and published studies do not answer them. The human pilot reports used injections into the knee, the bladder wall and a vein, each given by clinicians ^{[8] [9] [10]}.

In the 2003 rat Achilles study, BPC-157 was given by intraperitoneal injection once daily at 10 µg/kg, 10 ng/kg or 10 pg/kg of body weight ^[2]. The 2026 rat study used 10 µg/kg/day intraperitoneally for four weeks ^[12]. These are animal doses and should not be converted to human doses.

In the human pilot reports, the interstitial cystitis study used a total of 10 mg injected into the bladder wall in one procedure ^[9], and the intravenous safety study infused 10 mg on day one and 20 mg on day two in two participants ^[10]. The knee pain chart review did not report a standard dose in its abstract ^[8]. No human dose has been established by any controlled trial, and none of these figures is a recommendation. Our peptide calculator converts vial contents to concentrations, but it does not tell you what amount is appropriate.

Online BPC-157 dosage charts by body weight are not drawn from human trials, because none has set a dose. Questions about dosage in ml or syringe units are arithmetic rather than dosing. As an example of the arithmetic only, a vial labelled 10 mg dissolved in 2 mL of liquid gives 5 mg per mL, so 0.1 mL of that solution contains 0.5 mg; on a U-100 insulin syringe, 0.1 mL is marked as 10 units. Changing the volume of bacteriostatic water changes the concentration but not the total amount in the vial, and the calculation assumes the vial contains what its label says.

BPC-157 and TB-500 are often sold together, either as separate vials or as premixed blends, sometimes marketed as a “wolverine stack”. Only one published study has tested the two peptides together. In the 2026 Turkish rat study, adding TB-500 to BPC-157 after Achilles tendon repair gave no extra benefit over either peptide alone on tissue scores or tendon strength at four weeks ^[12]. The only human data involving both come from the knee pain chart review, in which four of 16 people received BPC-157 with thymosin beta-4; the report did not analyse them separately in a way that shows any added effect ^[8]. Everything published on the pairing is collected in BPC-157 and TB-500. What is and is not known about these blends is set out in Glow and Klow peptide blends.

We found no published study of a premixed BPC-157 and TB-500 blend, including the 10 mg and 20 mg blend vials sold online, and no study of three- or four-peptide blends that add GHK-Cu or KPV. There is also no published data on whether the two peptides are chemically stable when stored together in one vial. A BPC-157 TB-500 blend dosage calculator can only do the arithmetic of splitting a vial’s stated contents; it cannot draw on any trial, because none exists. For what is known about TB-500 on its own, see our TB-500 guide.

They are unrelated molecules. BPC-157 is a 15-amino-acid peptide based on a fragment of a gastric juice protein ^[1]. TB-500 is a seven-amino-acid acetylated fragment of thymosin beta-4, a protein that binds actin inside cells. Their proposed mechanisms differ: BPC-157 research centres on blood-vessel growth and the nitric oxide system ^[4], while thymosin beta-4 research centres on cell migration. In the only head-to-head study, in rats after Achilles repair, TB-500 gave a significant strength advantage at four weeks and BPC-157 gave non-significant improvements in tissue scores ^[12]. Both are prohibited in sport and neither is an approved medicine.

Animal studies from the originating group reported no toxicity ^[1], and reviews note few reports of adverse reactions in preclinical work ^[5]. The three human pilot reports described no adverse events, but they involved 30 people in total and short follow-up ^{[8] [9] [10]}. The 2025 systematic review found no clinical safety data and warned that harm is possible from unregulated manufacturing, contamination and unknown effects in humans ^[6].

Because BPC-157 promotes blood-vessel growth in laboratory models ^[4], some reviewers have raised the theoretical question of whether it could affect existing tumours; this has not been studied in people. The US Food and Drug Administration has said that compounded BPC-157 may carry a risk of immune reactions (immunogenicity) for some routes of administration and of peptide-related impurities, and that it lacked the safety information needed to judge whether it would cause harm ^[13].

On BPC-157 cancer risk specifically: we found no study showing that BPC-157 causes or promotes cancer, and no study designed to test whether it does. A 2026 review of unregulated injectable peptides listed pathological blood-vessel growth and cancer among the potential risks of BPC-157, TB-500 and similar products, alongside contamination and inaccurate dosing ^[20]. That is a stated concern, not an observed effect, but the absence of long-term human data means the risk cannot be ruled out either.

Is BPC-157 safe? No regulator has assessed it as safe for human use, and the published human data are too small to detect uncommon or delayed side effects. Reports of side effects in women, men or specific groups such as people who are pregnant do not come from any study we could find. The practical risks that are documented relate to product quality: unregulated vials may be mislabelled, under-filled or contaminated, which is why independent testing is covered in our guide to third-party peptide testing.

Pharmacokinetic work in rats and beagle dogs, published in 2022, found that BPC-157 has an elimination half-life of under 30 minutes after intravenous or intramuscular injection, that absolute bioavailability after intramuscular injection was about 14–19% in rats and 45–51% in dogs, and that it is broken down into small peptide fragments and amino acids that are excreted in urine and bile ^[11].

No human pharmacokinetic study has been published, so the half-life of BPC-157 in people is unknown. The dog data are also the only published data relevant to searches about BPC-157 for dogs; no veterinary treatment trial has been published.

BPC-157 is not approved as a medicine by the FDA, the UK’s MHRA or any other regulator we are aware of. In the US, the FDA previously placed it in “category 2” of its interim compounding policy, the list of bulk substances that may present significant safety risks; the nomination was later withdrawn and the FDA now lists it among substances previously in category 2 ^[13].

On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee met and considered BPC-157 for the list of bulk substances that US pharmacies may use for compounding under section 503A. The FDA’s meeting page posted no votes or outcome, and as of September 2026 the FDA has not acted ^[24]. The committee’s advice is not binding, a meeting does not make BPC-157 legal to compound, and inclusion on that list would still not make it an approved drug. Our US legal status page covers the wider rules.

BPC-157 is named on the World Anti-Doping Agency Prohibited List under S0, non-approved substances, and is prohibited at all times for athletes in WADA-compliant sport ^[14]. For country-by-country rules on buying and possessing research peptides, see our legal status overview and the UK page.

In Australia, BPC-157 is listed in Schedule 4 (prescription only) of the Poisons Standard and in Appendix D, clause 5, which means it must not be possessed without authority ^[27]. The TGA names BPC-157 as an example of an unapproved peptide product and says that a “research use only” label does not make its supply lawful ^[28]. As a prescription-only substance, it cannot lawfully be sold over the counter in Australian pharmacies or health shops. Details are on our Australia legal status page.

In New Zealand, Medsafe classifies BPC-157 and its analogues as prescription medicines ^[29]. In Canada, a Health Canada advisory of April 2026 named BPC-157 among seized unauthorised peptide products and said that “research use only” labelling does not make such products legal ^[15]. In the UK, BPC-157 is not a licensed medicine; the rules on selling, importing and possessing it are summarised on the UK page linked above.

Research suppliers sell BPC-157 as a freeze-dried (lyophilised) powder. Like other peptides, the dry powder is generally kept cold and away from light and moisture, and once dissolved it is kept refrigerated and used within a limited period. Our guide on how to store peptides covers the general principles.

Products sold as BPC-157 are unregulated, so purity and identity depend on the supplier. You can compare prices across suppliers we track, learn how to read a COA, and see which vendors use third-party tested batches.

Prices and availability differ by market. We track listings for BPC-157 UK prices, the US and Australia, and the legal position in each market is different, as described above. Branded capsules and tablets sold as supplements are not assessed differently on our pages: none has published trial data, so the checks that matter are the same, starting with a batch-specific certificate of analysis. Our guide to spotting a fake peptide supplier lists common warning signs.